The updated UK Haemophilia Centre Doctors' Organization guidelines provide recommendations for the treatment and management of von Willebrand disease, superseding the 1994 edition.
Provides updated UK guidelines for the treatment and management of von Willebrand disease.
von Willebrand disease (VWD) is the commonest inherited bleeding disorder. The aim of therapy for VWD is to correct the two defects of haemostasis in this disorder, impaired primary haemostasis because of defective platelet adhesion and aggregation and impaired coagulation as a result of low levels of factor VIII. The objective of this guideline is to inform individuals making choices about the treatment and management of VWD including the use of therapeutic products. This is the second edition of this UK Haemophilia Centre Doctors' Organization (UKHCDO) guideline and supersedes the previous edition which was published in 1994.
Pasi et al. (Thu,) conducted a review in von Willebrand disease (VWD). Treatment and management guidelines was evaluated. The updated UK Haemophilia Centre Doctors' Organization guidelines provide recommendations for the treatment and management of von Willebrand disease, superseding the 1994 edition.